New drug combo aims to keep aggressive myeloma at bay
NCT ID NCT06947083
First seen Dec 11, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This phase 2 trial tests whether the drug elranatamab, given as maintenance therapy after CAR-T cell treatment (cilta-cel), can delay cancer progression in people with high-risk relapsed myeloma. The study enrolls 39 patients whose myeloma has features like high-risk mutations or growth outside bones. Researchers will measure how long participants live without their myeloma worsening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elranatamab (a drug given as maintenance therapy after CAR-T cell treatment)
What this could lead to
If it works, this could help people with high-risk myeloma stay in remission longer after CAR-T therapy, delaying the return of the cancer.
What could go wrong
This is a small, early-phase study (39 people) with no control group, so results may not apply broadly. Elranatamab can cause side effects like infections or immune reactions, and the benefit over standard care is unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.